168 related articles for article (PubMed ID: 14768297)
1. Medical aspects of drug use in the gym.
Drug Ther Bull; 2004 Jan; 42(1):1-5. PubMed ID: 14768297
[TBL] [Abstract][Full Text] [Related]
2. [Doping: effectiveness, consequences, prevention].
Guezennec CY
Ann Endocrinol (Paris); 2001 Feb; 62(1 Pt 1):33-41. PubMed ID: 11240405
[TBL] [Abstract][Full Text] [Related]
3. Ergogenic aids: a review of basic science, performance, side effects, and status in sports.
Tokish JM; Kocher MS; Hawkins RJ
Am J Sports Med; 2004 Sep; 32(6):1543-53. PubMed ID: 15310585
[TBL] [Abstract][Full Text] [Related]
4. [Doping and urologic tumors].
Pinto F; Sacco E; Volpe A; Gardi M; Totaro A; Calarco A; Racioppi M; Gulino G; D'Addessi A; Bassi PF
Urologia; 2010; 77(2):92-9. PubMed ID: 20890867
[TBL] [Abstract][Full Text] [Related]
5. Performance-enhancing drugs.
Med Lett Drugs Ther; 2004 Jul; 46(1187):57-9. PubMed ID: 15263874
[No Abstract] [Full Text] [Related]
6. Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?
Tentori L; Graziani G
Pharmacol Res; 2007 May; 55(5):359-69. PubMed ID: 17349798
[TBL] [Abstract][Full Text] [Related]
7. Ergogenic drugs in sports.
Knopp WD; Wang TW; Bach BR
Clin Sports Med; 1997 Jul; 16(3):375-92. PubMed ID: 9209817
[TBL] [Abstract][Full Text] [Related]
8. [Cardiovascular complications of doping products].
Demoulin R; Poyet R; Capilla E; Tortat AV; Pons F; Brocq FX; Druelle A; Jego C; Foucault G; Cellarier GR
Ann Cardiol Angeiol (Paris); 2018 Nov; 67(5):365-369. PubMed ID: 30290907
[TBL] [Abstract][Full Text] [Related]
9. Performance enhancement drugs: safe and effective?
Clem JR
S D J Med; 2004 Jun; 57(6):215-6. PubMed ID: 15253475
[No Abstract] [Full Text] [Related]
10. Doping in sport: effects, harm and misconceptions.
Birzniece V
Intern Med J; 2015 Mar; 45(3):239-48. PubMed ID: 25369881
[TBL] [Abstract][Full Text] [Related]
11. [The use of drugs to improve athletic performance].
Kuipers H; Hartgens F
Ned Tijdschr Geneeskd; 1997 Oct; 141(41):1965-8. PubMed ID: 9550746
[TBL] [Abstract][Full Text] [Related]
12. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.
Pope HG; Wood RI; Rogol A; Nyberg F; Bowers L; Bhasin S
Endocr Rev; 2014 Jun; 35(3):341-75. PubMed ID: 24423981
[TBL] [Abstract][Full Text] [Related]
13. Anabolic agents.
Sturmi JE; Diorio DJ
Clin Sports Med; 1998 Apr; 17(2):261-82. PubMed ID: 9580841
[TBL] [Abstract][Full Text] [Related]
14. [Use of anabolic androgenic steroids, growth hormone and erythropoietin by patients in general practice].
Keld DB; Hahn T
Ugeskr Laeger; 2006 Sep; 168(37):3121-4. PubMed ID: 16999915
[TBL] [Abstract][Full Text] [Related]
15. Drugs and sport. Research findings and limitations.
Clarkson PM; Thompson HS
Sports Med; 1997 Dec; 24(6):366-84. PubMed ID: 9421862
[TBL] [Abstract][Full Text] [Related]
16. Performance-enhancing drug use in young athletes.
Laos C; Metzl JD
Adolesc Med Clin; 2006 Oct; 17(3):719-31; abstract xii. PubMed ID: 17030288
[TBL] [Abstract][Full Text] [Related]
17. Performance enhancing drug abuse and cardiovascular risk in athletes: implications for the clinician.
Angell PJ; Chester N; Sculthorpe N; Whyte G; George K; Somauroo J
Br J Sports Med; 2012 Nov; 46 Suppl 1():i78-84. PubMed ID: 23097484
[TBL] [Abstract][Full Text] [Related]
18. Stay alert for performance-enhancing substance use.
Jarvi JF
JAAPA; 2004 Dec; 17(12):36-9. PubMed ID: 15631019
[No Abstract] [Full Text] [Related]
19. Supplement use in the adolescent athlete.
DesJardins M
Curr Sports Med Rep; 2002 Dec; 1(6):369-73. PubMed ID: 12831686
[TBL] [Abstract][Full Text] [Related]
20. Performance-enhancing drugs.
Dandoy C; Gereige RS
Pediatr Rev; 2012 Jun; 33(6):265-71; quiz 271-2. PubMed ID: 22659257
[No Abstract] [Full Text] [Related]
[Next] [New Search]
